Lomustine

Also known as: CCNU Chloroethylcyclohexylnitrosourea

Active ingredient description

Lomustine’s mode of action is believed to be partly as an alkylating agent and partly by inhibition of several steps in the synthesis of nucleic acid and inhibition of the repair of single strand breaks in DNA chains.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01AD02
Lomustine
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AD Nitrosoureas
Discover more medicines within L01AD02

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
LOMUSTINE MEDAC Capsule
Summary of Product Characteristics (SPC)
UK

Medicines

Lomustine is the active ingredient of these drugs:

Drug
Countries
BELUSTINE

Netherlands

CECENU

Estonia Romania

CEENU

Canada Estonia New Zealand

CITOSTAL

Brazil

GLEOSTINE

United States

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₉H₁₆ClN₃O₂
Molecular mass: 233.695 g/mol

External identifiers

CAS Substance: 13010-47-4
DrugBank Drug: DB01206
KEGG Drug: D00363
PubChem Compound: 3950
RxNorm Ingredient: 6466
SNOMED-CT Concept: 387227009
Lomustine (substance)
UNII Identifier: 7BRF0Z81KG
LOMUSTINE
 
Next: Usage >